<DOC>
	<DOCNO>NCT00315042</DOCNO>
	<brief_summary>This multinational , randomize ( 1:1 ) , double blind , double dummy , comparator-controlled , 2 parallel treatment group study subject 6 month &lt; 13 year age , Streptococcus pyogenes tonsillitis/pharyngitis ( T/P ) .Each subject receive either telithromycin 25 mg/kg daily 5 day penicillin V , 13.3 mg/kg three time daily 10 day . Matching placebo telithromycin penicillin V also dispense 5 10 day respectively , provide blind different treatment regimen . A positive rapid identification test streptococcal Group A antigen require subject Visit 1 ( Day 1 ) entry study . Throat swab specimens bacterial culture , identification , antibiotic-susceptibility test take Visits 1 , 3 4 .</brief_summary>
	<brief_title>TELI TON - Telithromycin Tonsillitis</brief_title>
	<detailed_description />
	<mesh_term>Pharyngitis</mesh_term>
	<mesh_term>Tonsillitis</mesh_term>
	<mesh_term>Penicillins</mesh_term>
	<mesh_term>Telithromycin</mesh_term>
	<criteria>Age 6 month le 13 year age ( &lt; 13 ) ; Clinical diagnosis acute tonsillitis/pharyngitis cause Streptococcus pyogenes base : A positive result rapid detection throat swab test Group A streptococcal antigen submission throat swab specimen bacterial culture , identification , antibioticsusceptibility testing ; A sore scratchy throat and/or pain swallowing ( odynophagia ) together least 2 follow clinical sign : Tonsil and/or pharyngeal erythema and/or exudate ; Cervical adenopathy ; Uvular edema ; Fever Symptoms collectively suggest nonstreptococcal T/P ( eg , laryngitis , coryza , conjunctivitis , diarrhea , cough ) ; History positive throat culture Streptococcus pyogenes absence clinical sign symptom T/P ; Infection deep tissue upper respiratory tract ( eg , epiglottitis , retropharyngeal buccal cellulitis , abscess retropharynx , tonsil , peritonsillar area ) suprapharyngeal respiratory tract connect structure ( eg , sinusitis , otitis medium , orbital/periorbital cellulitis ) ; History rheumatic heart disease ; Females childbearing potential ( ie , reach menarche ) ; Known congenital prolong QT syndrome ; Known suspect uncorrected hypokalemia ( ≤3 mmol/L [ mEq/L ] ) , hypomagnesemia bradycardia ( &lt; 50 bpm ) ; Myasthenia gravis ; Known impair renal function , show creatinine clearance ≤25 mL/min The subject : Is treat drug permit study protocol ie , cisapride , pimozide , astemizole , terfenadine , ergotamine , dihydroergotamine , Class IA ( eg , quinidine procainamide ) Class III ( eg , dofetilide ) antiarrhythmic agent , simvastatin , lovastatin atorvastatin ; Is currently treat systemic antibacterial treat systemic antibacterial within 14 day prior enrollment ; Has treat investigational medication within last 30 day ; Has treat rifampicin , phenytoin , carbamazepine , St. John 's wort within last 2 week . History hypersensitivity intolerance macrolides , penicillin , cephalosporin ; Previous enrollment study previous treatment telithromycin ; Children investigator subinvestigator , research assistant , pharmacist , study coordinator , staff , relative thereof directly involve conduct protocol .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Tonsillitis</keyword>
	<keyword>pharyngitis</keyword>
	<keyword>penicillin</keyword>
	<keyword>telithromycin</keyword>
	<keyword>ketolides</keyword>
	<keyword>clinical trial</keyword>
</DOC>